Therapie der überaktiven Blase (OAB)

详细信息    查看全文

• 作者：Dr. M. Kurosch ; R. Mager ; K. Gust ; M. Brandt ; H. Borgmann ; A. Haferkamp
• 关键词：überaktive Blase ; Medikament?se Therapie ; Intravesikale Therapie ; Sakrale Neuromodulation ; Harnableitung ; Overactive urinary bladder ; Drug therapy ; Intravesical treatment ; Sacral neuromodulation ; Urinary diversion
• 刊名：Der Urologe A
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：54
• 期：4
• 页码：567-576
• 全文大小：473 KB
• 参考文献：1.Tran K, Levin RM, Mousa SA (2009) Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction. Adv Urol 345324
  2.Burgio KL, Goode PS, Johnson TM et al (2011) Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. J Am Geriatr Soc 59:2209-216View Article PubMed
  3.Giglio D, Tobin G (2009) Muscarinic receptor subtypes in the lower urinary tract. Pharmacology 83:259-69View Article PubMed
  4.Abrams P, Andersson KE, Buccafusco JJ et al (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565-78View Article PubMed Central PubMed
  5.Wagg A, Khullar V, Michel MC et al (2014) Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial. Neurourol Urodyn 33:106-14View Article PubMed
  6.Andersson KE, Arner A (2004) Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 84:935-86View Article PubMed
  7.Michel MC, Vrydag W (2006) Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147(Suppl 2):88-19View Article
  8.Otsuka A, Shinbo H, Matsumoto R et al (2008) Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol 377:473-81View Article PubMed
  9.Wuest M, Eichhorn B, Grimm MO et al (2009) Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-adrenoceptors in man. J Pharmacol Exp Ther 328:213-22View Article PubMed
  10.Tyagi P, Tyagi V (2010) Mirabegron, a beta(3)-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs 13:713-22PubMed
  11.Lee J, Moy S, Meijer J et al (2013) Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. Clin Drug Investig 33:429-40View Article PubMed
  12.Chapple CR, Dvorak V, Radziszewski P et al (2013) A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J 24:1447-458View Article PubMed Central PubMed
  13.Chapple CR, Kaplan SA, Mitcheson D et al (2013) Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 63:296-05View Article PubMed
  14.Herschorn S, Barkin J, Castro-Diaz D et al (2013) A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 82:313-20View Article PubMed
  15.Khullar V, Amarenco G, Angulo JC et al (2013) Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 63:283-95View Article PubMed
  16.Nitti VW, Auerbach S, Martin N et al (2013) Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 189:1388-395View Article PubMed
  17.Nitti VW, Khullar V, Van Kerrebroeck P et al (2013) Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 67:619-32View Article PubMed Central PubMed
  18.Schulte-Baukloh H, Priefert J, Knispel HH et al (2013) Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: a single-blind study. Urology 81:1052-057View Article PubMed
  19.Haferkamp A, Schurch B, Reitz A et al (2004) Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 46:784-91View Article PubMed
  20.Collins VM, Daly DM, Liaskos M et al (2013) OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium. BJU Int 112:1018-026PubMed
  21.Apostolidis A, Popat R, Yiangou Y et al (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174:977-82View Article PubMed
  22.Fowler CJ, Auerbach S, Ginsberg D et al (2012) OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol 62:148-57View Article Pu
• 作者单位：Dr. M. Kurosch (1)
  R. Mager (1)
  K. Gust (1)
  M. Brandt (1)
  H. Borgmann (1)
  A. Haferkamp (1)
  
  1. Klinik für Urologie und Kinderurologie, Universit?tsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Urology and Andrology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-0563

文摘

Overactive bladder (OAB) is a symptom complex which is present in approximately 17- of the European population. It is observed in the presence or absence of incontinence (wet or dry) and is associated with a high degree of psychological stress as well as high costs for the healthcare system. Myogenic, urothelial and neurogenic factors lead to frequently unknown changes of muscular, neural and connective tissue. For the definition, etiology and diagnostics of the disease the previous continuing medical education (CME) article “Diagnosis of overactive bladder (OAB)-should be consulted. In recent years some improvements have been made in OAB-related research, in terms of pathophysiological models and new pharmacological approaches with the development of new therapeutic agents. Besides classical substances, recently approved agents are increasingly being used for the therapy of OAB. Furthermore, non-pharmaceutical approaches and surgical techniques still play an important role in the therapy of OAB.